

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

<p>Bombay Stock Exchange Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: July 1, 2015</p>	
<p>Re.: Press Release.</p>	

Dear Sir / Madam,


We enclose herewith a copy of press release dated July 1, 2015 under the title “**Zydus receives market authorisation for Morphine Sulfate ER Tablets**”. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH
COMPANY SECRETARY

Encl.: As above.

Zydus receives market authorisation for Morphine Sulfate ER Tablets

Ahmedabad, 1 July 2015

The Zydus group has received the market authorisation from the USFDA to market Morphine Sulfate ER Tablets.

The product used in the treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St. Louis, USA.

A subsidiary of Zydus Pharmaceuticals (USA) Inc., Nesher has considerable expertise in niche therapies with development of products barriers, such as controlled release medications and DEA-controlled substances.
